...
首页> 外文期刊>Journal of Clinical Microbiology >Rapid Identification of Mycobacteria and Drug-Resistant Mycobacterium tuberculosis by Use of a Single Multiplex PCR and DNA Sequencing
【24h】

Rapid Identification of Mycobacteria and Drug-Resistant Mycobacterium tuberculosis by Use of a Single Multiplex PCR and DNA Sequencing

机译:通过使用单一多重PCR和DNA测序快速鉴定分枝杆菌和耐药结核分枝杆菌

获取原文
           

摘要

Tuberculosis (TB) remains a significant global health problem for which rapid diagnosis is critical to both treatment and control. This report describes a multiplex PCR method, the Mycobacterial IDentification and Drug Resistance Screen (MID-DRS) assay, which allows identification of members of the Mycobacterium tuberculosis complex (MTBC) and the simultaneous amplification of targets for sequencing-based drug resistance screening of rifampin-resistant (rifampinr), isoniazidr, and pyrazinamider TB. Additionally, the same multiplex reaction amplifies a specific 16S rRNA gene target for rapid identification of M. avium complex (MAC) and a region of the heat shock protein 65 gene (hsp65) for further DNA sequencing-based confirmation or identification of other mycobacterial species. Comparison of preliminary results generated with MID-DRS versus culture-based methods for a total of 188 bacterial isolates demonstrated MID-DRS sensitivity and specificity as 100% and 96.8% for MTBC identification; 100% and 98.3% for MAC identification; 97.4% and 98.7% for rifampinr TB identification; 60.6% and 100% for isoniazidr TB identification; and 75.0% and 98.1% for pyrazinamider TB identification. The performance of the MID-DRS was also tested on acid-fast-bacterium (AFB)-positive clinical specimens, resulting in sensitivity and specificity of 100% and 78.6% for detection of MTBC and 100% and 97.8% for detection of MAC. In conclusion, use of the MID-DRS reduces the time necessary for initial identification and drug resistance screening of TB specimens to as little as 2 days. Since all targets needed for completing the assay are included in a single PCR amplification step, assay costs, preparation time, and risks due to user errors are also reduced.
机译:结核病(TB)仍然是一个重要的全球性健康问题,对其进行快速诊断对于治疗和控制均至关重要。本报告介绍了多重PCR方法,分枝杆菌鉴定和耐药筛选(MID-DRS)分析方法,该方法可鉴定结核分枝杆菌复合体(MTBC)的成员,并同时扩增用于测序的利福平耐药性筛查的靶标耐药性(rifampin r ),异烟肼 r 和吡嗪酰胺 r TB。此外,相同的多重反应可扩增特定的16S rRNA基因靶标,以快速鉴定鸟分枝杆菌复合物(MAC)和热休克蛋白65基因的一个区域( hsp65 ),以进一步基于DNA测序确认或鉴定其他分枝杆菌种类。用MID-DRS与基于培养的方法对总共188个细菌分离株产生的初步结果的比较表明,MID-DRS对MTBC的敏感性和特异性分别为100%和96.8%。用于MAC识别的100%和98.3%;利福平 r 结核病的检出率为97.4%和98.7%;异烟肼 r 结核病的检出率为60.6%和100%;吡嗪酰胺 r 结核病鉴定的分别为75.0%和98.1%。 MID-DRS的性能也在耐酸细菌(AFB)阳性临床标本上进行了测试,检测MTBC的敏感性和特异性分别为100%和78.6%,检测MAC的敏感性和特异性分别为100%和97.8%。总之,使用MID-DRS可将结核病标本的初步鉴定和耐药性筛查所需的时间缩短至2天。由于完成测定所需的所有靶标都包含在单个PCR扩增步骤中,因此也降低了测定成本,制备时间和因用户错误引起的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号